Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regenxbio Inc (RGNX)

Regenxbio Inc (RGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Regenxbio Inc 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 USA

www.regenxbio.com Employees: 353 P: 240-552-8181

Sector:

Medical

Description:

REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.

Key Statistics

Overview:

Market Capitalization, $K 666,705
Enterprise Value, $K 609,175
Shares Outstanding, K 50,623
Annual Sales, $ 83,330 K
Annual Net Income, $ -227,100 K
Last Quarter Sales, $ 29,730 K
Last Quarter Net Income, $ -61,940 K
EBIT, $ -154,930 K
EBITDA, $ -142,860 K
60-Month Beta 1.14
% of Insider Shareholders 12.79%
% of Institutional Shareholders 88.08%
Float, K 44,148
% Float 87.21%
Short Interest 5,424
Short Float 10.72%
Short Volume Ratio 0.39

Growth:

1-Year Return 73.87%
3-Year Return -39.28%
5-Year Return -72.27%
5-Year Revenue Growth 136.53%
5-Year Earnings Growth -40.80%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.20 on 11/06/25
Next Earnings Date 03/12/26
Earnings Per Share ttm -3.47
EPS Growth vs. Prev Qtr 13.04%
EPS Growth vs. Prev Year -2.56%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

RGNX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -78.29%
Return-on-Assets % -34.49%
Profit Margin % -272.53%
Debt/Equity 0.00
Price/Sales 8.57
Price/Cash Flow N/A
Price/Book 4.41
Book Value/Share 3.20
Interest Coverage -16.94
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar